rHuman IL-7 Active, Human cytokinesand growth factors
- Known as:
- rHuman Interleukin-7 Active, Human cytokinesand growth factors
- Catalog number:
- RF0069-50
- Product Quantity:
- 50
- Category:
- -
- Supplier:
- Agren
- Gene target:
- rHuman IL-7 Active Human cytokinesand growth factors
Related genes to: rHuman IL-7 Active, Human cytokinesand growth factors
- Gene:
- IL7 NIH gene
- Name:
- interleukin 7
- Previous symbol:
- -
- Synonyms:
- IL-7
- Chromosome:
- 8q21.13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-10-12
- Date modifiied:
- 2016-10-11
- Gene:
- IL7R NIH gene
- Name:
- interleukin 7 receptor
- Previous symbol:
- -
- Synonyms:
- CD127, IL7RA
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2019-04-23
Related products to: rHuman IL-7 Active, Human cytokinesand growth factors
Related articles to: rHuman IL-7 Active, Human cytokinesand growth factors
- Recombinant human interleukin-7 hybrid Fc (rhIL-7-hyFc) is a homodimer of rhIL-7 fused to a hyFc. Exogenous IL-7 promotes T cell proliferation and increases lymphocyte count, making it a potential treatment option for lymphopenia and cancer. To improve therapeutic efficacy, rhIL-7-hyFc was developed as a long-acting IL-7. This study aimed to create a pharmacokinetic model for rhIL-7-hyFc by incorporating neonatal Fc receptor (FcRn)-mediated recycling and target-mediated drug disposition (TMDD) of the IL-7 receptor. Data were collected from a randomized, double-blind, placebo-controlled phase 1 trial involving 30 healthy volunteers who received single doses of rhIL-7-hyFc. Volunteers received 20 or 60 mg/kg subcutaneously, 60 mg/kg intramuscularly (IM), or a placebo. Clinical data were provided by Genexine Inc. (Seoul, Republic of Korea). A TMDD-FcRn-mediated recycling pharmacokinetic model was developed using NONMEM 7.5 software, assisted by PsN 5.3.1 software. A quasi-steady-state approximation was used to describe drug-receptor and drug-FcRn interactions. The model evaluation included goodness of fit, visual predictive checks, and bootstrap analysis. Based on the pharmacokinetic parameters of the final model, a simulation was conducted to select the dosage regimen, ensuring a probability of at least 0.8 for meeting both safety and efficacy criteria. The model successfully described the pharmacokinetic profiles of 24 patients administered rhIL-7-hyFc. Based on the simulation results, 670-800 μg/kg every 3 weeks, 1010-1530 μg/kg every 6 weeks, and 1510-2190 μg/kg every 9 weeks IM were proposed. These results may help further understand rhIL-7-hyFc characteristics and, moreover, provide guidance for selecting the appropriate dosing regimen in future clinical trials. - Source: PubMed
Jeon Hye SeonLee Sang WonJung WoojinJung HeeyoonChoi DonghoonByun Mi-SunYun Hwi-YeolLee SoyoungKim AnhyeChae Jung-WooLee Howard - Dry eye disease (DED) is a very common ocular surface disease that affects millions of people around the world. When we look at the pathogenesis of the disease, it is seen that inflammation plays a role. Ankylosing spondylitis (AS) is the prototype of immune-mediated inflammatory rheumatoid diseases in the spectrum of axial spondyloarthropathies. In studies, many proinflammatory cytokines (TNF-α, IL-23, IFN-γ), especially IL-17, have been shown in the etiopathogenesis of AS. Recently, anti IL-17 receptor inhibitors (secukinumab) have been using. It selectively binds to the IL-17 receptor, preventing its association with the target receptor. From this point of view, it was aimed to evaluate the blood and tear proinflammatory cytokine levels and ocular surface parameters of the patients treated with secukinumab, before and during the treatment. - Source: PubMed
Publication date: 2025/05/20
Dikmetas OzlemKapucu YaseminCoşan SemihRustamova NargizOzsoy ZehraKocabeyoglu SibelKalyoncu UmutTan ÇağmanTezcan İlhanIrkec Murat - Salivary gland epithelial cells (SGECs) play a key role in Sjögren's disease (SjD) as an active contributor to the pathogenesis. Current models lack clear epithelial readouts. Our aim was to establish a more advanced model by developing salivary gland organoids (SGOs) from labial salivary gland biopsies (LSGBs) of SjD patients and sicca controls. - Source: PubMed
Publication date: 2025/05/19
Meudec LoïcGoudarzi NegaarSilva-Saffar Sacha EPascaud JulietteJaulin FannyPascal QuentinLazure ThierryBechara RamiMariette XavierNocturne Gaetane - To probe the diagnostic value of direct eosinophils (EOS) count and vascular endothelial growth factor (VEGF) in bronchial asthma (BA) and their correlation with inflammatory factors and lung function indicators. - Source: PubMed
Publication date: 2025/05/19
Liu LongqunZhang ChenfeiXu JianHu Wei - Intratumoral immunotherapy delivers immune-modifying therapeutic agents directly into the tumor microenvironment (TME), stimulating both local and systemic immune responses. In this pilot study, we evaluated the immunomodulatory effects of cowpea mosaic virus (CPMV) particles, which primarily activates innate immunity, and calreticulin nanoparticle (CRT-NP), which enhance immunostimulatory signals of immunogenic cell death in canine cancers. The study focused on their potential to induce local and systemic antitumor immune responses and achieve tumor control. - Source: PubMed
Publication date: 2025/05/02
Singh AkanshaAffonso de Oliveira Jessica FernandaSchrader JessicaKishore DeepanChandrasekar Sri VidhyaFiering StevenSteinmetz Nicole FRanjan Ashish